The Boring Back & Forth of Social Interactions: Advice from People with ADHD

by Cynthia Hammer

Note: the following is a collection of perspectives from different people with ADHD. The * indicates another person’s input. 

This article was of interest to me because I did have people tell me over the years that I did not have good social skills. I at times struggle with small talk.   – Greg

Social Interactions & ADHD: Why We Get Bored 

*Small talk can be profoundly boring. The older you get, the more this is true. Truly, it is hard to find people who “match” in terms of what they find stimulating.

*Yesterday I talked with a friend who also has ADHD about how typical conversations go.   One person says his whole monologue and then the other person says her whole monologue. The monologue-ing gets so boring it is hard for us to stay engaged.

We prefer conversations where people interrupt with interesting tidbits as this makes the conversation more engaging and exciting.  Our preferred way of communicating is perfectly acceptable although there are settings where we need to reel in our enthusiasms and engage in more socially acceptable ways

*The more I work on conversation skills, the more I find the “take turns to dump” style grating, It’s hard to follow the conversation and contribute anything meaningful.  My brain wanders off when I try to sit and wait my turn! read more

Meet the company trying precision medicine for autism

by Giorgia Gugliemi

Swiss biotech Stalicla hopes to bring precision medicine to autism. Experts praise efforts to identify autism subgroups, but evidence to support the company’s claims has yet to be seen.

Five years ago, Lynn Durham founded a biotech startup — called Stalicla — that aims to do what nobody has achieved so far: tailor pharmacological therapies to idiopathic autism subgroups, or those who have autism with no known genetic cause. To date, the company, which is based in Switzerland, has secured 29 million Swiss francs ($30 million) and developed a machine-learning platform that sorts autistic people into different groups based on shared biological ‘signatures’ and then identifies drugs that it hopes will reverse such signatures. read more